Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -112,576 | -48,441 | -203,819 | -128,896 | -56,891 |
| Depreciation Amortization | 121 | 62 | 220 | 161 | 97 |
| Accounts payable and accrued liabilities | -3,480 | -793 | 4,909 | -409 | 1,860 |
| Other Working Capital | 5,539 | 4,096 | -7,944 | -12,509 | -13,492 |
| Other Operating Activity | 40,578 | 14,472 | 58,851 | 34,745 | -5,713 |
| Operating Cash Flow | $-69,818 | $-30,604 | $-147,783 | $-106,908 | $-74,139 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -16,153 | -11,471 | -174,670 | -153,629 | -156,177 |
| PPE Investments | -118 | -38 | -246 | -146 | -104 |
| Investing Cash Flow | $-16,271 | $-11,509 | $-174,916 | $-153,775 | $-156,281 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 22,106 | 11,065 | 31,106 | 17,422 | 11,530 |
| Other Financing Activity | 0 | 0 | -1,586 | -1,586 | -1,586 |
| Financing Cash Flow | $22,106 | $11,065 | $29,520 | $15,836 | $9,944 |
| Exchange Rate Effect | -1,832 | -1,332 | 12,759 | 12,819 | 12,597 |
| Beginning Cash Position | 491,323 | 491,323 | 771,743 | 771,743 | 771,743 |
| End Cash Position | 425,508 | 458,943 | 491,323 | 539,715 | 563,864 |
| Net Cash Flow | $-65,815 | $-32,380 | $-280,420 | $-232,028 | $-207,879 |
| Free Cash Flow | |||||
| Operating Cash Flow | -69,818 | -30,604 | -147,783 | -106,908 | -74,139 |
| Capital Expenditure | -118 | -38 | -246 | -146 | -104 |
| Free Cash Flow | -69,936 | -30,642 | -148,029 | -107,054 | -74,243 |